Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| CytRx Corp (QB) | CYTR | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.092 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.092 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0.00 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.092 | USD |
CytRx Corp (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 45.55k | 495.09k | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CytRx (QB) News
Real-Time news about CytRx Corp (QB) (OTCMarkets): 0 recent articles
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYTR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
CytRx (QB) Description
| LadRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs. The Company's focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. Four lead candidates (LADR-7 through LADR-10) were selected. CytRx has a milestone and royalty agreement with Orphazyme A/S for arimoclomol. Arimoclomol was subsequently sold to KemPharm ( now Zevra). The agreement can provide LadRx with potential milestones plus royalties paid on arimoclomol. Orphazyme is currently studying arimoclomol in clinical trials for Nieman-Pick disease Type C (NPC). Orphazyme filed an NDA with the FDA with Priority Review and received a Complete Response Letter on June 17, 2021. They held a Type A meeting with the FDA in October 2021, believe they have addressed the FDA's concerns and announced they will an NDA in 3Q23. For LadRx, this milestone and royalty agreement could represent potential near-term value for our company. LadRx also has a milestone and royalty agreement with ImmunityBio, Inc. for aldoxorubicin which is an improved version of the widely used chemotherapeutic agent doxorubicin. The agreement can provide LadRx with up to $343M in potential milestones + royalties paid on aldoxorubicin. |
